Viral Inactivation Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Viral Inactivation Market is Segmented by Method (Solvent Detergent Method, pH Adjustment Method, Pasteurization, and Others), Product (Viral Inactivation Systems and Accessories, Kits and Reagents, and Others), Application (Vaccines and Therapeutics, Blood & Blood Products, Cellular & Gene Therapy Products, and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organisations, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the values (USD million) for the above segments.

Viral Inactivation Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Viral Inactivation Industry Overview

The viral inactivation market is moderately consolidated, and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market with various development strategies. Some prominent players are making acquisitions and effective mergers to consolidate their market positions across the globe. Furthermore, new entrants are expected to enter the market with innovative product pipelines and continuous technological innovations that increase the market revenue over the forecast period. Some of the major market players are Cytiva (Danaher Corporation), Merck KGaA, Parker Hannifin Corp, Sartorius AG, and Texcell SA among others.

Viral Inactivation Market Leaders

  1. Merck KGaA

  2. Sartorius AG

  3. Texcell SA

  4. Cytiva (Danaher Corporation)

  5. Parker Hannifin Corp

  6. *Disclaimer: Major Players sorted in no particular order
4.png